BioSpace News Archive

Bionano Genomics, Inc. announced that it has received a letter from the staff of the Listing Qualifications department of the Nasdaq Stock Market LLC notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement set forth in Nasdaq Listing Rule 5550 for continued listing on the Nasdaq Capital Market.

Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting the supplemental New Drug Application (sNDA) for the full approval of LUMAKRAS® (sotorasib).

Avidity Biosciences, Inc. announced that on August 20, 2023, the Human Capital Management Committee of Avidity’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 42,100 shares of its common stock and 21,050 restricted stock units to thirteen new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.

ProMIS Neurosciences Inc. announced that it has entered into a securities purchase agreement with certain new and existing accredited investors to issue and sell an aggregate of approximately $20.4 million of common share units, each consisting of one of the Company’s common shares and one warrant to purchase one Common Share and pre-funded units, each consisting of one pre-funded warrant to purchase one Common Share and one Warrant.

Immune Biosolutions, a Canadian biotech company based in Sherbrooke, reached a new milestone in developing the first inhaled antibody-based treatment against COVID-19.

Exelixis, Inc. and Ipsen announced that the global phase 3 CONTACT-02 pivotal trial met one of two primary endpoints, demonstrating a statistically significant improvement in progression-free survival at the primary analysis.

Masimo announced the findings of a prospective, randomized study published in Perioperative Medicine in which Dr. Yu Wang and colleagues at institutions in Shenzhen, Shaoguan, and Guangzhou, China evaluated the use of noninvasive, continuous Masimo PVi®, as part of goal-directed fluid therapy, to guide intraoperative fluid administration during gastrointestinal surgery on elderly patients by comparing it to conventional fluid therapy.

Recently, magAssist’s NyokAssist™ Interventional Ventricular Assist Device, has been granted designation as a breakthrough device by the U.S. Food and Drug Administration in Breakthrough Device Program.

Inhalis Therapeutics SA, a pioneering privately-held company specializing in advanced inhaled treatments for life-threatening diseases, proudly reveals a significant stride forward as it submits a new patent application on INHAL-101, its lead asset.

Johnson & Johnson announced that, based on preliminary results, its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of Kenvue Inc. common stock owned by Johnson & Johnson was oversubscribed.